Furthermore, in some studies of squamous NSCLC and renal cell carcinoma, the efficacy of PD-1 blockade (response rate or survival outcome) in PD-L1− patients was similar to or even better than that in PD-L1+ patients (5, 201). The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.